Author

J. Okosun

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Clear· 1 shared A. D'Avola· 1 shared A. F. Al Seraihi· 1 shared A. Melnick· 1 shared A. Yeomans· 1 shared B. Sale· 1 shared D. Barisic· 1 shared D. P. Calado· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Clear

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Mutations in the IgG B cell receptor associated with class-switched B cell lymphomas

L. Wasim, S. W. T. Chu, B. Sale, L. Pickard, S. Leonard, L. Zhang, H. Tolarova, Z. S. Tean, N. Engels, D. P. Calado, K. Tarte, J. Okosun, F. Forconi, P. Tolar

This study identifies mutations in the IgG heavy chain in follicular lymphoma and EZB DLBCL that enhance BCR signalling and oncogenicity by disrupting the IgG intracellular tail.

bioRxiv · Apr 12, 2024 · PreprintImmunology

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

J. A. Heward, L. Koniali, A. D'Avola, K. Close, A. Yeomans, M. Philpott, J. Dunford, T. Rahim, A. F. Al Seraihi, J. Wang, K. Korfi, S. Araf, S. Iqbal, F. Bewicke-Copley, E. Kumar, , J. Fitzgibbon

This study shows that inhibiting KDM5 demethylases restores H3K4 methylation and reactivates genes in KMT2D mutant lymphomas, offering a potential therapeutic strategy.

bioRxiv · Jun 30, 2020Cancer Biology